Journal article
Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
P Sasanejad, L Afshar Hezarkhani, S Arsang-Jang, G Tsivgoulis, A Ghoreishi, B Kristian, J Rahmig, M Farhoudi, E Sadeghi Hokmabadi, A Borhani-Haghighi, P Sariaslani, A Sharifi-Razavi, K Ghandehari, A Khosravi, C Smith, Y Nilanont, Y Akbari, TN Nguyen, A Bersano, N Yassi Show all
Journal of Stroke and Cerebrovascular Diseases | Published : 2021
Abstract
Background: There is little information regarding the safety of intravenous tissue plasminogen activator (IV-tPA) in patients with stroke and COVID-19. Methods: This multicenter study included consecutive stroke patients with and without COVID-19 treated with IV-tPA between February 18, 2019, to December 31, 2020, at 9 centers participating in the CASCADE initiative. Clinical outcomes included modified Rankin Scale (mRS) at hospital discharge, in-hospital mortality, the rate of hemorrhagic transformation. Using Bayesian multiple regression and after adjusting for variables with significant value in univariable analysis, we reported the posterior adjusted odds ratio (OR, with 95% Credible Int..
View full abstract